Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 P649 | DOI: 10.1530/endoabs.90.P649

ECE2023 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (159 abstracts)

Serum Follistatin-Like-1(FSTL-1) Levels in Gestational Diabetes and The Role of FSTL-1 Gene Polymorphism in the Development of Gestational Diabetes Mellitus

Ender Celik 1 , Gulhan Akbaba 2 , Tuba Edgünlü 3 , Eren Akbaba 4 , Fatih Pirincci 4 & Nese Cinar 4


1Muğla Sitki Kocman University Faculty Of Medicine, Internal Medicine, Turkey; 2Muğla Sitki Kocman University Faculty Of Medicine, Endocrinology, Turkey, 3Muğla Sitki Kocman University Faculty Of Medicine, Medical Biology, Turkey, 4Muğla Sitki Kocman University Faculty Of Medicine, Obstetrics And Gynecology, Turkey


Introduction: Gestational Diabetes Mellitus (GDM) is associated with maternal and perinatal morbidity. Follistatin-like 1 (FSTL-1), also known as TGFB-beta-stimulated clone 36 (TSC-36), is a glycoprotein cardiokine reported to be associated with insulin resistance and inflammatory processes. To date, there is no study evaluating the effect of FSTL-1 gene polymorphism on the development of GDM in the literature. In this study, we aimed to investigate the effect of serum FSTL-1 level and FSTL-1 gene rs12173 and rs869247 polymorphism in the development of GDM.

Material and Method: Demographic characteristic sand metabolic parameters (FSTL-1, fasting plasma glucose, fasting insulin, HbA1c) of all participants were evaluated. DNA was isolated from peripheral blood. Genotype and allele frequencies were determined by PCR-RFLP method. The prevalences of FSTL-1 polymorphism of the patient sand controls were compared.

Results: 72 patients with GDM (meanage: 29.54±4.56 years) and 79 healthy pregnant women (meanage: 28,27±4,47 years) were included in the study. GDM patients had significantly higher BMI than the control group (27.44±5.46 kg/m2 vs. 25.39±2.96 kg/m2, p<0.001). The mean HbA1c % in the GDM group was found to be higher than in the control group (5.11±0.42% vs. 4.92±0.30%, p=0.002). There was no significant difference in the serum FSTL-1 levels between the groups (339.35±293.59 ng/mL for GDM and 414.53±364.09 ng/mL for control group; p=0.917). 11 GDM patients (15.3%) had CC genotype, 22 (30.6%) had CT genotype, and 39 patients (54.2%) had TT genotype of FSTL-1 gene rs12173 polymorphism. The prevalence of CC-, CT- and TT- genotypes, in the control group was 11.4, 20.3, and 68.4% respectively-similar prevalences as in the patient group (p:0.097). 24 GDM patients (33.3.%) had CC genotype, 38 (52.8%) had CT genotype, and 10 patients (13.9%) had TT genotype of FSTL-1 gene rs869247 polymorphism. There was no difference in the distribution of the genotypes of FSTL-1 gene rs869247 polymorhism between the groups (24.1, 65.8, and 10.1%forCC-, CT- and TT- genoypes, in the control group, p: 0.264). There was no difference in the allele frequencies of FSTL-1 gene rs12173 and rs869247 polymorphism between the groups (p=0.086 andp=0.627, respectively).

Conclusion: FSTL-1 gene rs12173 and rs869247 polymorphism seemed to have no effect on the development of GDM. Large-scale studies are needed to find out the molecular mechanisms of FSTL-1 on metabolic diseases

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.